Triple-Target Immunotherapy for Solid Tumors Advances – Novel Antibody Enters Pivotal Testing Phase
A Chinese biopharmaceutical company has cleared a major regulatory milestone with a groundbreaking approach to cancer immunotherapy. As reported by PharmaBiz.com, the FDA has authorized CStone Pharmaceuticals to begin phase…